FDA confirms date for Exact Sciences' advisory committee Exact Sciences announced that the U.S. Food and Drug Administration has confirmed by notice in the Federal Register that its Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee will review the premarket approval application for the company’s Cologuard stool-DNA-based, non-invasive colorectal cancer screening test on March 27.
News For EXAS From The Last 14 Days
Check below for free stories on EXAS the last two weeks.
Exact Sciences checks show robust early adoption trends, says Jefferies Jefferies says its analysis of Exact Sciences' enrollment database indicates robust early adoption of Cologuard. The firm has increased conviction in its 2015 test volume forecasts and keeps a Buy rating on the stock with a $20 price target.
Exact Sciences volatility elevated Exact Sciences October call option implied volatility is at 88, November is at 78, January is at 71; compared to its 26-week average of 66 according to Track Data, suggesting large near term price movement.